A Retrospective/Prospective, Multicenter, Non-interventional, Historical Control Study Investigating Comparative Effectiveness of IMBRUVICA in Steroid Dependent/Refractory cGVHD Patients
Latest Information Update: 02 Apr 2024
At a glance
- Drugs Ibrutinib (Primary) ; Corticosteroids
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- Sponsors Janssen
- 28 Apr 2023 Status changed from recruiting to discontinued.
- 21 Jun 2021 Planned End Date changed from 31 Dec 2024 to 31 Jan 2025.
- 21 Jun 2021 Planned primary completion date changed from 30 Sep 2024 to 31 Jan 2025.